179128-84-8

Basic information

• Product Name: (E)-3-(3,4-bis(allyloxy)phenyl)acrylic acid
• Synonyms: (E)-3-(3,4-bis(allyloxy)phenyl)acrylic acid
• CAS NO: 179128-84-8
• Molecular Weight: 260.29
• Mol File: 179128-84-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (E)-3-(3,4-bis(allyloxy)phenyl)acrylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(3,4-bis(allyloxy)phenyl)acrylic acid(179128-84-8)
• EPA Substance Registry System: (E)-3-(3,4-bis(allyloxy)phenyl)acrylic acid(179128-84-8)

Safety Data

• Hazardous Substances Data: 179128-84-8(Hazardous Substances Data)

Upstream product

• 139-85-5 3,4-dihydroxybenzaldehyde 
• 331-39-5 caffeic acid 
• 203118-27-8 3-(3,4-bis-allyloxyphenyl)acrylic acid allyl ester 
• 141-82-2 malonic acid 
• 71186-67-9 3,4-diallyloxybenzaldehyde 

Downstream Products

• 70185-64-7 N-trans-caffeoyltyramine 
• 105955-00-8 3-(3,4-dihydroxy-phenyl)-N-[2-trans-(3,4-dihydroxy-phenyl)-ethyl]-acrylamide 
• 928765-97-3 Serotomide 
• 84744-28-5 calceolarioside A 

Relevant articles and documents

ROSMARINIC ACID DERIVATIVE OR SALT THEREOF

The present invention provides a compound that inhibits the activity of TRPV4 and is useful for prevention or amelioration of an overactive bladder, an irritable bowel syndrome, etc. The compound is a rosmarinic acid derivative represented by the followin

ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY

Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.

A non-enzymatic synthesis of (S)-(-)-rosmarinic acid and a study of a biomimetic route to (+)-rabdosiin

The synthesis of (S)-(-)-rosmarinic acid (30) in 9% overall yield is described. The synthesis was achieved by a convergent route in which 3-(3′,4′-dihydroxyphenyl)-(S)-lactic acid (23) and caffeic acid (25), both appropriately protected, were coupled to produce a pentaallyl precursor 29, which was then deprotected to give (S)-(-)-rosmarinic acid (30). A triallyl derivative 35 was similarly prepared and converted to (+)-rabdosiin (41) and its (1R,2S) isomer (42) via a biomimetic oxidative free radical coupling-cyclization followed by deallylation. The coupling-cyclization gave a ratio of rabdosiin diastereomers unlike that found in nature. A preliminary study showed that methyl (R)-mandelyl sinapate (15) could be dimerized diastereoselectively to give a 1,2-trans thomasidioate diester (16). The synthesis of (S)-(-)-rosmarinic aid (30) in 9% overall yield is described. The synthesis was achieved by a convergent route in which 3- (3',4'-dihydroxyphenyl)-(S)-lactic acid (23) and caffeic acid (25), both appropriately protected, were coupled to produce a pentaallyl precursor 29, which was then deprotected to give (S)-(-)-rosmarinic acid (30). A triallyl derivative 35 was similarly prepared and converted to (+)-rabdosiin (41) and its (1R,2S) isomer (42) via a biomimetic oxidative free radical coupling- cyclization followed by deallylation. The coupling-cyclization gave a ratio of rabdosiin diastereomers unlike that found in nature. A preliminary study showed that methyl (R)-mandelyl sinapate (15) could be dimerized diastereoselectively to give a 1,2-trans thomasidioate diester (16).